The Impact of Multiple Malignancies on Patients with Bladder Carcinoma: A Population-Based Study Using the SEER Database

Table 4

Stage adjusted survival rates and Cox hazard ratios for BO and BS cohorts, multivariate analysis.

		5-yr overall	10-yr overall	5-yr	10-yr	5-yr bladder	10-yr bladder
				CA specific	CA specific	CA specific	CA specific
BO, low stage (𝑛=81,129)	survival rate	0.73	0.53	0.90	0.85	0.92	0.88
	HR	0.519	0.562	0.255	0.252	0.423	0.462
	95% CI	(0.497, 0.542)	(0.540, 0.584)	(0.242, 0.269)	(0.240, 0.264)	(0.396, 0.452)	(0.433, 0.492)
BS, low stage (𝑛=18,778)	survival rate	0.71	0.46	0.78	0.59	0.96	0.92
	HR	0.537	0.642	0.596	0.738	0.223	0.285
	95% CI	(0.511, 0.564)	(0.616, 0.670)	(0.563, 0.631)	(0.702, 0.775)	(0.202, 0.245)	(0.262, 0.311)
BO, high-stage (𝑛=28,972)	survival rate	0.28	0.18	0.39	0.33	0.43	0.38
	HR	1.802	1.682	1.700	1.546	2.644	2.586
	95% CI	(1.727, 1.880)	(1.619, 1.748)	(1.620, 1.783)	(1.479, 1.615)	(2.486, 2.813)	(2.438, 2.744)
BS, high-stage (𝑛=4,961)	survival rate	0.46	0.27	0.54	0.39	0.72	0.65

HRs reported with 95% confidence intervals (95% CI). All HRs were calculated using the high-stage BS cohort as the reference group. SEER staging classification.